files selected
ClearLearn about the Home Infusion process and how your patient can receive their migraine treatment at home.
Explore this brief overview of CGRP in migraine pathophysiology and the science behind therapeutic antibodies, including the purposeful design of VYEPTI.
Discover the intentional design features of eptinezumab-jjmr.
This guide includes helpful tips for discussing VYEPTI migraine prevention with your patients, including what they may expect from their IV treatment.
Step-by-step instructions for the preparation and administration of VYEPTI.
Watch Electra discuss her experience with chronic migraine and VYEPTI.
Watch Dr Dawn C Buse, PhD, and Dr Andrew C Charles, MD, as they speak with Electra, a real migraine patient treated with VYEPTI. Learn about efficacy and safety data for VYEPTI and patient considerations when selecting treatment.
Explore the pivotal trial results for eptinezumab-jjmr in episodic migraine.
Explore the pivotal trial results for eptinezumab-jjmr in chronic migraine.
See a variety of resources that can help support your VYEPTI patients.
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.
VYEPTI is indicated for the preventive treatment of migraine in adults.
Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Prescribing Information and Patient Information.
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.
VYEPTI is indicated for the preventive treatment of migraine in adults.
Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Prescribing Information and Patient Information.